340 related articles for article (PubMed ID: 25123150)
41. C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis.
Pinto AE; André S; Pereira T; Nóbrega S; Soares J
Ann Oncol; 2001 Apr; 12(4):525-33. PubMed ID: 11398888
[TBL] [Abstract][Full Text] [Related]
42. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.
Anders CK; Hsu DS; Broadwater G; Acharya CR; Foekens JA; Zhang Y; Wang Y; Marcom PK; Marks JR; Febbo PG; Nevins JR; Potti A; Blackwell KL
J Clin Oncol; 2008 Jul; 26(20):3324-30. PubMed ID: 18612148
[TBL] [Abstract][Full Text] [Related]
43. JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer.
Reedijk M; Pinnaduwage D; Dickson BC; Mulligan AM; Zhang H; Bull SB; O'Malley FP; Egan SE; Andrulis IL
Breast Cancer Res Treat; 2008 Oct; 111(3):439-48. PubMed ID: 17990101
[TBL] [Abstract][Full Text] [Related]
44. Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients.
Sicking I; Rommens K; Battista MJ; Böhm D; Gebhard S; Lebrecht A; Cotarelo C; Hoffmann G; Hengstler JG; Schmidt M
BMC Cancer; 2014 Dec; 14():952. PubMed ID: 25511800
[TBL] [Abstract][Full Text] [Related]
45. APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma.
Rüder U; Denkert C; Kunze CA; Jank P; Lindner J; Jöhrens K; Kulbe H; Sehouli J; Dietel M; Braicu E; Darb-Esfahani S
Histol Histopathol; 2019 Apr; 34(4):405-417. PubMed ID: 30289149
[TBL] [Abstract][Full Text] [Related]
46. Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer.
Zhao CL; Singh K; Brodsky AS; Lu S; Graves TA; Fenton MA; Yang D; Sturtevant A; Resnick MB; Wang Y
BMC Cancer; 2019 Nov; 19(1):1036. PubMed ID: 31675929
[TBL] [Abstract][Full Text] [Related]
47. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y
Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866
[TBL] [Abstract][Full Text] [Related]
48. Outcomes of locally advanced breast cancer patients with ≥ 10 positive axillary lymph nodes.
Koca E; Kuzan TY; Dizdar O; Babacan T; Sahin I; Ararat E; Altundag K
Med Oncol; 2013; 30(3):615. PubMed ID: 23729267
[TBL] [Abstract][Full Text] [Related]
49. In vivo and in vitro studies suggest a possible involvement of HPV infection in the early stage of breast carcinogenesis via APOBEC3B induction.
Ohba K; Ichiyama K; Yajima M; Gemma N; Nikaido M; Wu Q; Chong P; Mori S; Yamamoto R; Wong JE; Yamamoto N
PLoS One; 2014; 9(5):e97787. PubMed ID: 24858917
[TBL] [Abstract][Full Text] [Related]
50. CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
Alfarsi LH; Ansari RE; Craze ML; Toss MS; Masisi B; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 Dec; 178(3):535-544. PubMed ID: 31471836
[TBL] [Abstract][Full Text] [Related]
51. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
Nimmrich I; Sieuwerts AM; Meijer-van Gelder ME; Schwope I; Bolt-de Vries J; Harbeck N; Koenig T; Hartmann O; Kluth A; Dietrich D; Magdolen V; Portengen H; Look MP; Klijn JG; Lesche R; Schmitt M; Maier S; Foekens JA; Martens JW
Breast Cancer Res Treat; 2008 Oct; 111(3):429-37. PubMed ID: 17965955
[TBL] [Abstract][Full Text] [Related]
52. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.
Liu R; Guo CX; Zhou HH
Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514
[TBL] [Abstract][Full Text] [Related]
53. Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab.
Wang X; Cai L; Ye F; Li M; Ma L; Geng C; Song Z; Liu Y
Medicine (Baltimore); 2019 Sep; 98(36):e16937. PubMed ID: 31490377
[TBL] [Abstract][Full Text] [Related]
54. Improved Prognostication for the Updated AJCC Breast Cancer Pathological Prognostic Staging Varied in Higher-Stage Groups.
Hu J; Fung MW; Tsang JY; Poon IK; Chan SK; Cheung SY; Hu H; Zhou D; Tse GM
Clin Breast Cancer; 2020 Jun; 20(3):253-261.e7. PubMed ID: 32205037
[TBL] [Abstract][Full Text] [Related]
55. High expression of OSR1 as a predictive biomarker for poor prognosis and lymph node metastasis in breast cancer.
Li Y; Qin J; Wu J; Dai X; Xu J
Breast Cancer Res Treat; 2020 Jul; 182(1):35-46. PubMed ID: 32424721
[TBL] [Abstract][Full Text] [Related]
56. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
[TBL] [Abstract][Full Text] [Related]
57. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
Razis E; Kalogeras KT; Kotoula V; Eleftheraki AG; Nikitas N; Kronenwett R; Timotheadou E; Christodoulou C; Pectasides D; Gogas H; Wirtz RM; Makatsoris T; Bafaloukos D; Aravantinos G; Televantou D; Pavlidis N; Fountzilas G
Clin Breast Cancer; 2012 Jun; 12(3):183-93. PubMed ID: 22607768
[TBL] [Abstract][Full Text] [Related]
58. Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer.
Kim SH; Ahn S; Suh KJ; Kim YJ; Park SY; Kang E; Kim EK; Kim IA; Chae S; Choi M; Kim JH
Breast Cancer Res Treat; 2020 Oct; 183(3):697-704. PubMed ID: 32715441
[TBL] [Abstract][Full Text] [Related]
59. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
[TBL] [Abstract][Full Text] [Related]
60. A high level of estrogen-stimulated proteins selects breast cancer patients treated with adjuvant endocrine therapy with good prognosis.
L H Weischenfeldt K; Kirkegaard T; Rasmussen BB; Giobbie-Hurder A; Jensen MB; Ejlertsen B; Lykkesfeldt AE
Acta Oncol; 2017 Sep; 56(9):1161-1167. PubMed ID: 28488912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
